Global Cancer Biological Therapy Market 2018 Size, Development Status, Type and Application, Segmentation, Forecast by 2023

WiseGuyReports.com adds “Cancer Biological Therapy Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023”reports to its database.

Pune, India - January 12, 2018 /MarketersMedia/ —

Cancer Biological Therapy Market:

Executive Summary

Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. There are various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as; cancer targeted therapies.

The global cancer biological therapy market is expected to reach USD 82,276.8 million by 2023 at a CAGR of 4.7% during the forecasted period.  

The global cancer biological therapy market is segmented on the basis of phases, types, end users and regions. On the basis of phases, the market is segmented into phase I, phase II and phase III. In stage I & II the real impact of these therapies is seen and giving a success rate of 35% in Phase 1 and 20% in Phase II. The success rate of phase I is 35%.

On the basis on types, the global cancer biological therapy market is segmented into monoclonal antibodies, cancer growth blockers, interferons, interleukins, gene therapy, targeted drug delivery, colony stimulating factor, cancer vaccines and others. Monoclonal antibodies accounted for the largest market share of the global cancer biological therapy market. Colony stimulating factor is the fastest growing market at a CAGR of 5.2% during the forecasted period.

On the basis on end users, hospitals & clinics dominates the global cancer biological therapy market. Registering USD 26,790.6 million in 2016 and expected to reach at USD 38,471.9 million by 2023 at the rate of 4.4 % from 2016-2023. 

On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific and the Middle East & Africa. North America has the dominating market for cancer biological therapy. The cancer biological therapy market for North America is estimated at USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Players

The leading market players in the global cancer biological therapy market include Merck Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Bristol-Myers Squibb, Celgene, ELI Lilly and Company, EnGeneIC, and Pfizer

Study objectives

To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global cancer biological therapy market
To provide insights about factors influencing and affecting the market growth
To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
To provide historical and forecast revenue of the market segments based on channels, applications, and regions for the global cancer biological therapy market.
To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
To provide economical factors that influences the global cancer biological therapy market
To provide detailed analysis of the value chain and supply chain of the global cancer biological therapy market

Target Audience

Pharmaceutical Companies
Pharmaceutical Suppliers
Cancer Research Organizations
Potential Investors
Key Executive (CEO and COO) and Strategy Growth Manager
Reaserch Companies

For further information on this report, visit - https://www.wiseguyreports.com/enquiry/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Findings

North America accounted for the largest market share in the global cancer biological therapy market, USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%
Colony stimulating factor is the fastest growing segment with a CAGR of and 5.2% in the global cancer biological therapy market, by types
Hospitals and clinics is contributing remarkable share in the market registering 47.8% in the global cancer biological therapy market, by end users in 2016

The reports also covers regional analysis

North America
o US

o Canada

Europe
o Germany

o France

o U.K.

o Italy

o Spain

o Rest of Europe

Asia Pacific
o Japan

o China

o India

o Republic of Korea

o Rest of Asia-Pacific

Middle East & Africa
o Middle East

o Africa

Continuous…

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1793685

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: Wise Guy Research Consultants Pvt Ltd
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349 (US); +44 208 133 9349 (UK)

Source URL: https://marketersmedia.com/global-cancer-biological-therapy-market-2018-size-development-status-type-and-application-segmentation-forecast-by-2023/286775

For more information, please visit https://www.wiseguyreports.com/reports/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Source: MarketersMedia

Release ID: 286775

More News From Biz Daily Online

Asian shares drift lower as China data, trade cast shadows

Jul 17, 2018

BANGKOK — Shares edged lower in Asia early Monday after China reported lackluster growth data in line with expectations. Geopolitical and trade tensions were weighing on sentiment despite gains last week on Wall Street. KEEPING SCORE: The Shanghai Composite index lost 0.4 percent to 2,820.52 and Hong Kong's Hang Seng edged less than 0.1 percent lower to 28,486.70. The Kospi in South Korea fell 0.2 percent to 2,307.06 and Australia's S&P ASX 200 gave up 0.3 percent to 6,246.80. Shares fell in Southeast Asia and Taiwan. Japan's market was closed for a holiday. WALL STREET LAST WEEK: Stocks wrapped up...

Asian shares mostly higher; Japan's Nikkei up on weak yen

Jul 17, 2018

SEOUL, South Korea — Asian shares are mostly higher, rebounding from jitters over the U.S.-China trade disputes for a second straight day. KEEPING SCORE: Japan's Nikkei 225 jumped 1.3 percent to 22,483.13 and South Korea's Kospi gained 0.8 percent to 2,302.32. Hong Kong's Hang Seng index added 0.3 percent to 28,578.86. But Shanghai Composite Index in mainland China fell 0.6 percent to 2,821.73. In Australia, S&P-ASX 200 dipped 0.2 percent to 6,255.10. Stocks in Singapore, Taiwan and other Southeast Asian markets were higher. ANALYST'S TAKE: Despite recent escalations in trade battles, "the sky hasn't fallen just yet as optimism crept...

Asian markets rebound from trade fears

Jul 17, 2018

BEIJING — Asian stock markets rose Thursday following Wall Street's decline amid U.S.-Chinese trade tensions and oil prices recovered some of the previous day's steep losses. KEEPING SCORE: The Shanghai Composite Index rose 1.1 percent to 2,809.42 and Tokyo's Nikkei 225 gained 1.2 percent to 22,181.13. Sydney's S&P-ASX 200 added 0.7 percent to 6,258.00 and Seoul's Kospi advanced 0.4 percent to 2,289.31. Benchmarks in Taiwan and Southeast Asia also rose. Hong Kong's Hang Seng was unchanged at 28,309.61. New Zealand declined. TRADE TENSION: China's government said it will take "firm and forceful measures" if the Trump administration goes ahead with...

Chinese tech giant Tencent plans US listing for music arm

Jul 17, 2018

BEIJING — Tencent, China's most valuable tech company and the operator of the popular WeChat social media platform, says it plans to spin off its streaming music service on a U.S. stock exchange. The company said in a statement issued through the Hong Kong stock exchange that the share price and other details of the stock offering in Tencent Music Entertainment Group have yet to be decided. Tencent Holdings Ltd.'s other businesses include WeChat and online games and video. Most of its activity is concentrated in its faster-growing home market in China but the company is gradually expanding abroad. Tencent...

US-China trade battle kicks off; markets take it in stride

Jul 17, 2018

BEIJING — The United States and China launched what Beijing called the "biggest trade war in economic history" Friday, imposing tariffs on billions of dollars of each other's goods amid a spiraling dispute over technology. The Trump administration is confronting China over development tactics it says include stealing technology or pressuring foreign companies to hand it over. American officials worry U.S. industrial leadership will be eroded by Chinese plans to create tech champions in fields including robotics, biotech and artificial intelligence. Washington imposed 25 percent duties on $34 billion of imports from China, the first in a series of possible...

About Us

Biz Daily Online gives a complete understanding of the world of business to you. Get today’s business news and learn about the trends that are affecting every business here.

Contact us: sales[at]bizdailyonline.com

Subscribe Now!